Page last updated: 2024-08-16

triazolam and ritonavir

triazolam has been researched along with ritonavir in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's5 (55.56)29.6817
2010's3 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Blanco, R; Coles, R; Kharasch, ED; Mitchell, D1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Daily, JP; Greenblatt, DJ; Harmatz, JS; Shader, RI; von Moltke, LL1
Daily, JP; Durol, AL; Graf, JA; Greenblatt, DJ; Harmatz, JS; Hoffman, JL; Mertzanis, P; Shader, RI; von Moltke, LL1
Duan, SX; Durol, AL; Greenblatt, DJ; von Moltke, LL1
Greenblatt, DJ; Perloff, MD; von Moltke, LL1

Reviews

2 review(s) available for triazolam and ritonavir

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction.
    Journal of clinical psychopharmacology, 1999, Volume: 19, Issue:4

    Topics: Acquired Immunodeficiency Syndrome; Alprazolam; Animals; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; HIV Protease Inhibitors; Humans; Hypnotics and Sedatives; Metabolic Clearance Rate; Microsomes, Liver; Oxidoreductases, N-Demethylating; Ritonavir; Triazolam

1999

Trials

2 trial(s) available for triazolam and ritonavir

ArticleYear
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:5

    Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Bupropion; Cross-Over Studies; Cytochrome P-450 CYP2B6; Female; HIV Protease Inhibitors; Humans; Liver; Male; Oxidoreductases, N-Demethylating; Ritonavir

2008
Differential impairment of triazolam and zolpidem clearance by ritonavir.
    Journal of acquired immune deficiency syndromes (1999), 2000, Jun-01, Volume: 24, Issue:2

    Topics: Adult; Anti-Anxiety Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Double-Blind Method; Half-Life; HIV Protease Inhibitors; HIV Seronegativity; Humans; Hypnotics and Sedatives; Male; Metabolic Clearance Rate; Oxidoreductases, N-Demethylating; Pyridines; Ritonavir; Triazolam; Zolpidem

2000

Other Studies

5 other study(ies) available for triazolam and ritonavir

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole.
    European journal of clinical pharmacology, 2000, Volume: 56, Issue:3

    Topics: Aryl Hydrocarbon Hydroxylases; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Furans; Humans; Hydroxylation; Ketoconazole; Oxidoreductases, N-Demethylating; Ritonavir; Sulfonamides; Triazolam

2000
Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats.
    Xenobiotica; the fate of foreign compounds in biological systems, 2004, Volume: 34, Issue:2

    Topics: Algorithms; Animals; Anti-Inflammatory Agents; Antibodies, Blocking; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Blotting, Western; Capillaries; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Dexamethasone; Enzyme Induction; Enzyme Inhibitors; GABA Modulators; Gene Expression; HIV Protease Inhibitors; Intestines; Liver; Luminescent Measurements; Male; Microsomes; Oxidoreductases, N-Demethylating; Rats; Rats, Sprague-Dawley; Ritonavir; Triazolam

2004